2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
DNA X, Inc. received a letter on August 28, 2026, from a Nasdaq Hearings Panel saying the company has regained compliance with the $2.5 million stockholders' equity requirement. The company's securities remain subject to delisting if it fails to maintain compliance with all Nasdaq listing rules through November 18, 2026, and it is under a mandatory panel monitor until August 28, 2027. If the company falls below the equity requirement again during that period, it would get no compliance plan or extra time, and its securities could be delisted.
Panel determined the company regained compliance with the $2.5 million stockholders' equity requirement; letter dated August 28, 2026
Securities remain subject to delisting if the company fails to maintain compliance with all Nasdaq rules until November 18, 2026
Mandatory panel monitor runs until August 28, 2027; a new equity deficiency would lead to a delisting determination with no cure period
Microvast Holdings received a Nasdaq notice on August 26, 2026, saying its common stock closed below the $1 minimum bid price for 30 consecutive trading days. The shares remain listed and trading on Nasdaq, and the company has 180 days to regain compliance before any delisting process would begin, which shareholders should watch closely.
Notice received August 26, 2026, under Nasdaq Rule 5450(a)(1) for average closing bid price below $1 over 30 consecutive trading days
Common stock continues to trade on Nasdaq; a non-compliance indicator will appear on NASDAQ.com
Company has 180 days to regain compliance, subject to possible additional time
If not compliant, a delisting notice is expected; an appeal to a Nasdaq Hearings Panel could keep shares listed, but success is not assured
Nutex Health said an unauthorized third party accessed and took information from its servers, including patient, employee, provider, and business data, and has threatened to post it publicly. A class action lawsuit was filed August 27, 2026, and the company says it cannot predict the outcome or estimate the impact on its finances or stock price.
Unauthorized party accessed and exfiltrated data; third party has threatened to post it externally
Purported class action Haley v. Nutex Health, Case No. 4:26-cv-07197, filed August 27, 2026, in the U.S. District Court for the Southern District of Texas
To date, no material impact identified on business operations or financial reporting systems
Company intends to make required notifications, including to impacted patients
BridgeBio entered a voluntary agreement with the U.S. government to expand Medicaid access to Attruby through the GENEROUS Model and lower drug costs. The company says it does not expect to be subject to future pricing mandates, and the specific terms remain confidential.
Agreement expands state Medicaid access to Attruby via the GENEROUS Model; specific terms are confidential
BridgeBio does not expect future pricing mandates; pricing commitments for future medicines are expected to exclude medicines approved exclusively for orphan indications
ForgingBridges copay program is unaffected and can reduce out-of-pocket costs to as little as $0 per month
Pending FDA reviews include BBP-418 (PDUFA November 27, 2026) and encaleret (PDUFA May 7, 2027)
MicroVision received written notice from Nasdaq on August 26, 2026, confirming it had regained compliance with the $1 minimum bid price requirement under Listing Rule 5550(a)(2), and Nasdaq staff concluded the matter is closed. The company had first been notified of noncompliance on January 12, 2026. The filing removes a Nasdaq listing deficiency, but it does not disclose share prices, financial results, or other financial figures.
Nasdaq notice dated August 26, 2026 confirms regained compliance with the $1 minimum bid price rule (Listing Rule 5550(a)(2))
Company was first notified of noncompliance on January 12, 2026
Nasdaq Listing Qualifications staff concluded the matter is now closed; CEO Glen DeVos issued a press release dated August 31, 2026
Cadrenal Therapeutics said that at a Type D meeting with the U.S. Food and Drug Administration held July 28, 2026, the company and the FDA aligned on key aspects of the protocol and Statistical Analysis Plan for a Phase 3 registrational study of CAD-1005 in heparin-induced thrombocytopenia (HIT). The filing says the agreement sets the primary endpoint definition and the use of a placebo control, which the company says clarifies the regulatory path, but it does not disclose financial results, costs, or a trial start date.
Type D meeting with the FDA held July 28, 2026; the company announced the feedback on August 31, 2026.
Primary endpoint measures the proportion of Serotonin Release Assay-positive participants with adjudicated new or worsening composite thromboembolic events through Day 14 or hospital discharge.
The FDA agreed to a placebo control, with standard anticoagulation therapeutics in both the CAD-1005 and placebo arms.
The company states that approximately 50,000 patients in the U.S. have acute HIT each year.
PG&E Corporation will host a webcast and conference call on September 2, 2026, at 8:30 AM Eastern Time to provide an investor update, including its response to Senate Bill 492. The company said it does not believe the bill adequately addresses financing risks created by California's current wildfire liability framework, and that it falls short of providing the long-term durability needed to attract affordable investment.
Investor webcast and conference call set for Wednesday, September 2, 2026, at 8:30 AM Eastern Time
Company says Senate Bill 492 does not adequately address financing risks from California's wildfire liability framework
Replay available by phone at (800) 770-2030 with confirmation code 92587 through September 9, 2026
BioMarin entered a binding term sheet with Ascendis Pharma on August 30, 2026, to settle all pending proceedings over its patent rights covering the C-type natriuretic peptide TransCon CNP (navepegritide, Yuviwel). Ascendis will pay BioMarin royalties on Licensed Product sales, and the parties will dismiss all related litigation with prejudice, including the ITC Section 337 investigation. The filing gives no financial value for the settlement or the royalties beyond the rates, so the effect on BioMarin's results cannot be measured from this filing.
Royalty of 20% of annual net sales in the United States and 18% in the European Union, Brazil and South Korea, running until May 2030
BioMarin grants Ascendis a non-exclusive, worldwide, royalty-bearing license to its patents for all current and potential indications, including achondroplasia and hypochondroplasia
Term sheet is binding as of August 30, 2026; parties must sign the full Agreement by September 24, 2026, or the term sheet terms continue to bind
AiRWA Inc. (Nasdaq: YYAI) received a Nasdaq letter on August 24, 2026, saying it breached a listing rule by not filing its annual report on Form 10-K for the year ended April 30, 2026. The company blamed the delay on the time needed to consolidate a significant acquired business, and says the notice has no immediate effect on trading but that the filing and compliance are not assured.
Nasdaq letter dated August 24, 2026 cites Listing Rule 5250(c)(1) for the late 10-K.
Company must submit a compliance plan by October 23, 2026; Nasdaq may then grant an extension to January 25, 2027.
Company expects to file the 10-K before October 23, 2026, but the filing says there can be no assurance it will regain compliance.
Oragenics said NYSE American notified it on August 26, 2026 that it is below the continued listing standards for stockholders' equity. The company reported stockholders' equity of $3.7 million at June 30, 2026, and the exchange requires $6 million because the company had net losses in its five most recent fiscal years. The notice does not immediately affect the listing, but if the company does not meet the requirements, it could face delisting, which the filing says could reduce the stock's liquidity and market price.
Stockholders' equity was $3.7 million at June 30, 2026; the NYSE American standard cited requires $6 million.
A compliance plan is due to NYSE American by September 25, 2026, and the company must regain compliance by February 25, 2028.
Shares continue to trade as OGEN with a ".BC" (below compliance) designation during the plan period.
The company says it will endeavor to undertake a transaction in the future to achieve compliance, but gives no assurance it will succeed.
Socket Mobile received a Nasdaq notice dated August 24, 2026, saying it no longer meets the $2.5 million minimum stockholders' equity requirement, based on $2,382,624 reported in its June 30, 2026 quarterly report. The company must submit a compliance plan by October 8, 2026, and its stock continues to trade on the Nasdaq Capital Market under SCKT for now.
Stockholders' equity of $2,382,624 versus a $2.5 million Nasdaq minimum
Company also did not meet alternative standards: $35 million market value of listed securities or $500,000 net income from continuing operations
Compliance plan due October 8, 2026; Nasdaq may grant up to 180 calendar days if it accepts the plan
No immediate effect on listing or trading of SCKT common stock
GeoVax Labs received a Nasdaq Staff Determination Letter on August 27, 2026, stating Nasdaq will delist its common stock because the bid price stayed below $1.00 and the company is not eligible for the customary 180-day compliance period after its January 2026 reverse split. The company plans to request a hearing before the Nasdaq Hearings Panel, which would stay further action and keep the stock trading during the appeal, but the filing says there is no assurance the panel will grant continued listing.
Nasdaq determined the closing bid price was below $1.00 for 30 consecutive business days from July 16, 2026 through August 26, 2026.
The company effected a 1-for-25 reverse stock split on January 12, 2026, which made it ineligible for the 180-day compliance period.
Absent a timely hearing request, trading is expected to be suspended at the opening of business on September 8, 2026; the hearing request deadline is September 3, 2026.
My Size, Inc. received a Nasdaq letter on August 25, 2026, saying its stockholders' equity of $2,347,000 as of June 30, 2026 fell short of the $2,500,000 minimum for continued listing. The letter has no immediate effect on the listing, but the company must submit a compliance plan by October 9, 2026, and the Staff may grant an extension through February 21, 2027 if the plan is accepted.
Reported stockholders' equity as of June 30, 2026: $2,347,000 versus a $2,500,000 minimum under Nasdaq Listing Rule 5550(b)(1)
Compliance plan due October 9, 2026; the company plans to submit it on time
If accepted, extension possible through February 21, 2027; if not accepted or compliance is not regained, Staff would issue a delisting determination, which a hearing request would stay
Nasdaq staff determined to delist Jupiter Neurosciences' common stock from the Nasdaq Capital Market after the company did not regain compliance with the $35,000,000 minimum market value of listed securities by August 25, 2026. The company intends to appeal to the Nasdaq Hearings Panel and expects the hearing request to stay further action, but it cannot assure that the appeal will succeed. Separately, the company regained compliance with the $1.00 minimum bid price requirement, though the delisting threat remains.
Nasdaq notice received August 27, 2026 states the Staff determined to delist the common stock from The Nasdaq Capital Market.
Market value of listed securities was below the $35,000,000 minimum; the compliance deadline was August 25, 2026.
Company intends to request a hearing before the Nasdaq Hearings Panel and expects this to stay further action; success is not assured.
Closing bid price was at least $1.00 for 10 consecutive business days, August 13 through August 26, 2026, and the bid price matter is closed.
KALA BIO received a Nasdaq Staff Determination Letter on August 27, 2026, stating its common stock closed below $1.00 for 30 consecutive business days and it is out of compliance with the minimum bid price rule. Because the company effected a 1-for-50 reverse stock split on May 11, 2026, it is not eligible for a standard 180-day compliance period, and the company plans to request a Nasdaq Hearings Panel review, which would stay any delisting action while pending.
Nasdaq Staff determined the stock closed below $1.00 from July 16, 2026 through August 26, 2026, 30 consecutive business days.
No 180-day compliance period is available because the company effected a 1-for-50 reverse stock split on May 11, 2026.
KALA BIO intends to timely request a hearing before the Nasdaq Hearings Panel; a timely request stays suspension or delisting pending the Panel's decision.
The company states there is no assurance the Panel will grant continued listing or that it will regain compliance.
Southland's subsidiaries agreed on August 26, 2026 to pay Liberty Mutual $5 million by September 30, 2026 to resolve about $36.4 million of surety losses tied to the Washington State Convention Center project. Southland expects the settlement to favorably affect pre-tax income by about $29 million in the third quarter of 2026, though that estimate is preliminary and subject to accounting review.
Settlement with Liberty Mutual, Zurich American and Fidelity and Deposit covers about $36.4 million of surety losses, about $34 million of which relates to the WSCC Judgement.
Company will pay $5 million to Liberty on or before September 30, 2026.
Preliminary estimate: favorable impact of about $29 million on income before income taxes in Q3 2026, subject to change.
Negotiations with Zurich to resolve the remaining surety payable related to the WSCC Judgement are ongoing.
Rein Therapeutics received a Nasdaq notice on August 21, 2026, because its common stock closed below $1.00 per share over the previous 30 consecutive trading days. The company has until February 17, 2027 to regain compliance, and Nasdaq says it will start suspension and delisting procedures if compliance is not regained in time.
Notice received from Nasdaq on August 21, 2026 under Rule 5550(a)(1), the minimum $1.00 bid price standard
Compliance deadline is February 17, 2027, 180 days from the notice date
Regaining compliance requires a closing bid price of at least $1.00 for a minimum of 10 consecutive business days
Filing states there is no assurance of additional time after the initial 180-day period
A federal court in Nevada dismissed all claims the SEC brought against Live Ventures in its 2021 enforcement action, with no judgment, penalty, admission or findings against the company. CEO Jon Isaac separately agreed to a consent judgment with a $175,000 civil penalty on the individual claims against him, while denying the allegations.
Court dismissed all claims against Live Ventures in the SEC civil action, Case No. 2:21-cv-01433-JCM-MDC, filed August 2021
Company faced no judgment, penalty, admission or findings of any kind
Jon Isaac agreed to a consent judgment with a $175,000 civil penalty; he admits no wrongdoing and denies the allegations
Onfolio Holdings said Nasdaq has determined it regained compliance with the $1.00 minimum bid price rule, and Nasdaq considers the matter closed. The company received the original notice on July 2, 2026, and its closing bid price stayed at or above $1.00 from August 10 to August 25, 2026. The filing shows the company is no longer at risk of a Nasdaq listing action over this issue, but it does not give financial results.
Nasdaq notice on July 2, 2026 said the stock had failed to maintain a minimum bid price of $1.00 for 30 consecutive business days.
Closing bid price was at or above $1.00 for 12 consecutive business days, from August 10 to August 25, 2026.
Press release dated August 27, 2026 (Exhibit 99.1) announced the regained compliance under Nasdaq Listing Rule 5550(a)(2).
CEO Dominic Wells said the reverse split was enacted about two weeks before the release to restore compliance.
Atlantic American Corporation received a Nasdaq notice on August 20, 2026, stating it is not in compliance with listing rule 5250(c)(1) because it has not filed its second quarter 2026 Form 10-Q and remains delinquent on its 2025 Form 10-K and first quarter 2026 Form 10-Q. Nasdaq says the notice has no immediate effect on the listing of the common stock, but the company must meet the October 12, 2026 deadline to regain compliance.
Nasdaq notice dated August 20, 2026 cites Listing Rule 5250(c)(1) for late periodic reports.
Company must submit an updated compliance plan for the Form 10-Q by September 4, 2026.
Nasdaq extension to regain compliance runs until October 12, 2026; a Nasdaq Hearings Panel appeal is available if the plan is not accepted.
The notice has no immediate effect on the listing of the common stock on The Nasdaq Global Market.
On August 20, 2026, Nasdaq notified American Resources Corporation that it is not in compliance with Listing Rule 5250(c)(1) because it did not timely file its Form 10-Q for the quarter ended June 30, 2026. The notice has no immediate effect on the listing or trading of the company's common stock, but the March 10-Q remains delinquent, so the company's compliance timeline is tight.
Nasdaq notice dated August 20, 2026 cites late filing of the June 30, 2026 quarterly report on Form 10-Q.
The notice has no immediate effect on listing or trading of the common stock on The Nasdaq Capital Market.
The company must submit an amended plan addressing the June filing to Nasdaq by September 4, 2026.
If Nasdaq staff accepts the plan, the maximum extension for the June filing would be October 15, 2026, the same deadline previously granted for the March 10-Q.
The fund's sponsor signed a licensing agreement with FTSE International for the FTSE XRP Index, which will replace the CME CF XRP-Dollar Reference Rate for valuing shares and calculating net asset value starting August 27, 2026. The filing also amends the sponsor fee to be paid at least quarterly rather than weekly, and updates the trust agreement to reflect these changes, which the filing says do not materially affect shareholder rights.
Benchmark change follows CF Benchmarks licensing termination effective August 31, 2026, with the FTSE switch beginning August 27, 2026.
FTSE XRP Index licence is expected to have a one-year initial term, renewing automatically for one-year periods.
Sponsor fee payment timing changed from weekly in arrears to at least quarterly in arrears, still payable in XRP.
Fourth Amended and Restated Trust Agreement signed August 26, 2026 with CSC Delaware Trust Company as trustee.
ARK 21Shares Bitcoin ETF will value its shares and calculate net asset value using the FTSE Bitcoin Index instead of the CME CF Bitcoin Reference Rate - New York Variant, starting August 27, 2026, after the prior licensing agreement with CF Benchmarks is set to end August 31, 2026. The sponsor also changed the timing of its fee payments from weekly to at least quarterly, with the fee still paid in bitcoin, and the filing says the revisions to the trust agreement do not materially affect the rights of the trust or shareholders.
Benchmark switch: from August 27, 2026, the trust uses the FTSE Bitcoin Index in place of the CME CF Bitcoin Reference Rate - New York Variant for net asset value.
Licensing: the Benchmark Licensing Agreement with FTSE International Limited is dated August 20, 2026, with an expected one-year initial term that renews automatically.
Sponsor fee: Amendment No. 1, dated August 26, 2026, moves Sponsor Fee payments from weekly to at least quarterly in arrears, payable in bitcoin.
Documents: the trust agreement was restated on August 26, 2026 with the sponsor and CSC Delaware Trust Company as trustee.
Ensysce Biosciences said Nasdaq determined on August 25, 2026 that it complies with the $2.5 million stockholders' equity requirement, but the company remains subject to delisting if it does not evidence compliance in its next periodic report. Nasdaq also granted an extension on the minimum bid price rule to February 22, 2027, and said the Cy Biopharma transaction triggers a change of control requiring the post-transaction company to meet initial listing criteria, with trading suspension possible if it does not.
Nasdaq determined on August 25, 2026 that the company complies with the $2.5 million stockholders' equity requirement, but delisting remains possible if compliance is not evidenced in the next periodic report
Nasdaq granted an additional 180 calendar days, until February 22, 2027, to regain the $1.00 minimum bid price requirement
Nasdaq said the Cy Biopharma transaction, completed August 5, 2026, is a change of control requiring an initial listing application; failure could lead to trading suspension
The company intends to submit an initial listing application in a timely manner
Maison Solutions Inc. (Nasdaq: MSS) received a Nasdaq letter on August 20, 2026, saying it is not in compliance with listing rules because it did not timely file its Form 10-K for the fiscal year ended April 30, 2026. The letter has no immediate effect on the listing of the Class A common stock, which continues to trade on The Nasdaq Capital Market, but the company must still submit a compliance plan.
Nasdaq cited Listing Rule 5250(c)(1), which requires timely filing of periodic reports, after the Form 10-K for the year ended April 30, 2026 was not filed on time.
The company has until October 19, 2026 to submit a plan to regain compliance.
If Nasdaq accepts the plan, it may grant an exception until February 9, 2027; if not, the company may appeal to a Nasdaq Hearings Panel.
The company said it is working diligently to complete the Form 10-K and intends to submit the plan within the 60-day period.
Nasdaq told BEST SPAC I Acquisition Corp. on August 19, 2026 that its Market Value of Listed Securities has been below the $35,000,000 minimum over the last 30 consecutive business days, and that it also does not meet two other Nasdaq listing requirements. The notice has no immediate effect, and the company's units, Class A ordinary shares and rights keep trading on Nasdaq, but the company must regain compliance by February 15, 2027, or face possible delisting.
Nasdaq notice dated August 19, 2026 cites the $35,000,000 minimum MVLS under Listing Rule 5550(b)(2)
The company also does not meet Listing Rules 5550(b)(1) and 5550(b)(3)
Compliance period runs 180 calendar days, until February 15, 2027
Units (BSAAU), Class A ordinary shares (BSAA) and rights (BSAAR) continue trading for now
NextEra Energy filed supplemental disclosures to the joint proxy statement/prospectus for its pending merger with Dominion Energy, made after several purported NextEra shareholders sent demand letters alleging disclosure deficiencies. NextEra says the allegations are without merit and that the supplements are voluntary, aimed at avoiding cost and delay to the closing. The filing adds details on Lazard's valuation analyses, including peer multiples and a March 2026 standstill agreement with a third party, and does not report any change to deal terms.
Merger Agreement dated May 15, 2026; joint proxy statement/prospectus mailed on or about July 28, 2026
Supplemental disclosures cover Lazard's sum-of-the-parts and company comparables analyses, using May 15, 2026 pricing
A Non-Disclosure and Standstill Agreement with Party A was executed March 27, 2026
Hub Group received a Nasdaq notice on August 20, 2026 that it is not in compliance with Listing Rule 5250(c)(1) because it has not timely filed its quarterly report for the quarter ended June 30, 2026. The notice has no immediate effect on the listing or trading of the Class A common stock, but the company must submit an updated plan to regain compliance by August 27, 2026, and any further exception is capped at September 14, 2026.
Nasdaq notice dated August 20, 2026 cites late Form 10-Q for the quarter ended June 30, 2026 under Listing Rule 5250(c)(1)
Company must submit an updated compliance plan to Nasdaq by August 27, 2026
Delinquent 2025 Form 10-K and Q1 2026 Form 10-Q have an exception deadline of September 14, 2026
Notice has no immediate effect on listing or trading on the Nasdaq Global Select Market
Pantages Capital Acquisition Corporation received a Nasdaq notice on August 21, 2026, stating that its market value of listed securities has been below the $50 million minimum for 30 consecutive business days. Nasdaq said the notice is only a deficiency notification with no current effect on listing or trading, but the company has until February 17, 2027 to regain compliance or face a possible delisting notice.
Nasdaq notice dated August 21, 2026 cites the $50 million minimum market value of listed securities for continued listing on the Nasdaq Global Market.
The company also does not meet Nasdaq Listing Rule 5450(b)(3)(A), according to the notice.
Compliance Period runs 180 calendar days to February 17, 2027; regaining compliance requires at least $50 million for 10 consecutive business days.
The company says it is monitoring its market value and evaluating options, but gives no assurance it will regain or maintain compliance.
Beasley Broadcast Group received written notice from Nasdaq on August 19, 2026, confirming it has regained compliance with the $2,500,000 minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq has closed the matter, and the company's common stock continues to trade on Nasdaq under the ticker BBGI.
Nasdaq notice dated August 19, 2026 confirmed compliance with the minimum stockholders' equity requirement.
The deficiency was first flagged in a Nasdaq notice received April 13, 2026, under Listing Rule 5550(b)(1).
The minimum requirement is $2,500,000 in stockholders' equity for Nasdaq Capital Market companies.
Nasdaq has closed the matter, and the common stock remains listed under BBGI.
Capricor Therapeutics said the FDA extended the PDUFA target action date for the Deramiocel Biologics License Application from August 22, 2026 to November 22, 2026, after classifying the company's amendment as a major amendment. The amendment adds 24-month open-label extension data from the Phase 3 HOPE-3 study and seeks review for a refined indication focused on upper limb function, which delays the timing of a possible FDA decision on the therapy.
PDUFA target action date moved from August 22, 2026 to November 22, 2026, a three-month extension
FDA classified the submission as a major amendment and accepted it for review through CBER
Amendment includes 24-month open-label extension data from the HOPE-3 study and a request to review a refined indication focused on upper limb function
CEO Linda Marbán said HOPE-3 met its primary endpoint, a statistically significant benefit in upper limb function
A federal court in California ruled in several related cases involving Sable's Santa Ynez Pipeline System. The court found Sable violated the 2020 consent decree by restarting operations without state authorization, imposed a $1.449 million penalty, and declined to order a shutdown because the federal pipeline regulator PHMSA had approved the Restart Plan. The court also denied California's bid for a preliminary injunction against the federal Defense Production Act order, and California filed a notice of appeal on August 20, 2026.
Court found Sable violated the Consent Decree by restarting the onshore pipeline without OSFM authorization, but declined to order a shutdown.
Court imposed a $1.449 million penalty on the Company.
Court denied California's motion for a preliminary injunction against the DPA Order; California filed notice of appeal on August 20, 2026.
In a separate case, the court declared the DPA Order bars California Department of Parks and Recreation from suing to stop Sable's onshore operations; defendant filed notice of appeal on August 21, 2026.
On August 21, 2026, a Delaware federal jury returned a verdict in patent infringement action brought by Beckman Coulter against Cytek Biosciences. The jury found noninfringement and invalidity on three of four asserted claims, but found infringement under the doctrine of equivalents on one claim and awarded $20 million in lost profits and $36.11 million in royalties. The company plans post-verdict motions and may appeal, and says the verdict does not require changes to its current products or operations.
Jury found noninfringement and invalidity on three of the four asserted patent claims.
On the remaining claim, jury found no literal infringement but found infringement under the doctrine of equivalents.
Past damages awarded: $20 million in lost profits and $36.11 million in royalties.
Company intends to pursue post-verdict motions and may appeal to the Federal Circuit; it says its products remain available.
Nasdaq notified Roman DBDR Acquisition Corp. II on August 19, 2026, that it does not maintain the minimum of 400 holders required for continued listing. The notice has no immediate effect on the listing of the company's securities on the Nasdaq Global Market, but the company must submit a compliance plan, and failure to regain compliance could ultimately lead to delisting.
Nasdaq deficiency letter received August 19, 2026, under Listing Rule 5450(a)(2)
Compliance plan due to Nasdaq by October 5, 2026
If the plan is accepted, Nasdaq can grant an exception until February 15, 2027
If Nasdaq rejects the plan, the company may appeal to a Nasdaq Hearings Panel
SolarMax Technology received a Nasdaq notice on August 20, 2026, because it has not filed its Form 10-Q for the quarter ended June 30, 2026. The company has until October 19, 2026 to submit a plan to regain compliance, and Nasdaq could grant an exception to February 16, 2027 if it accepts that plan. The filing also discloses two earlier Nasdaq deficiencies, a bid price issue and a market value of listed securities issue, so shareholders face several open listing requirements at once.
Nasdaq notice dated August 20, 2026 cites Listing Rule 5250(c)(1) for the missing 10-Q for the quarter ended June 30, 2026
Plan to regain compliance due October 19, 2026; Nasdaq could allow an exception up to February 16, 2027 if the plan is accepted
Bid price deficiency notice received March 3, 2026; compliance deadline August 31, 2026; one-for-12 reverse stock split effected August 13, 2026
Market value of listed securities notice received June 22, 2026; compliance deadline December 21, 2026
Pasithea Therapeutics Corp. received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement, moving the deadline from August 19, 2026 to February 16, 2027. The company says it may consider a reverse stock split, and if it does not regain compliance, Nasdaq could begin delisting proceedings, though the company says there is no assurance it will meet the new deadline.
Nasdaq letter dated February 20, 2026 flagged closing bid price below $1.00 for 30 consecutive business days.
Original compliance deadline was August 19, 2026; extension granted in an August 20, 2026 Nasdaq letter to February 16, 2027.
Company may consider a reverse stock split; if not compliant by the deadline, Nasdaq would issue a delisting notice that the company could appeal to a hearings panel.
Estrella Immunopharma received a Nasdaq notice on August 17, 2026, stating its common stock closed below $1.00 for 30 consecutive business days, so it no longer meets the minimum bid price requirement. The notice has no immediate effect on trading, and the company has until February 16, 2027 to regain compliance, which could involve a reverse stock split.
Nasdaq letter dated August 17, 2026 cites closing bid price below $1.00 from July 6, 2026 through August 14, 2026
Compliance period runs 180 calendar days, until February 16, 2027
Common stock continues to trade on The Nasdaq Capital Market under the symbol ESLA
If not compliant by the deadline, the company may be eligible for a second 180-day period, or face delisting notice and an appeal
JAB Acquisition Corp I entered a trademark settlement agreement on August 17, 2026, with a third party over its name and trading symbol, and reported it in an August 21, 2026 filing. Under the agreement, the company has asked Nasdaq to change its ticker and intends to rename itself Atlantic Acquisition Corp I, effective once its board and shareholders approve. The filing says current shareholders need take no action and that share ownership percentages and the capital structure are unaffected.
Settlement agreement dated August 17, 2026, with a third party identified as the Claimant
Company has requested a voluntary ticker change from Nasdaq; no effective date has been announced
Proposed new ticker symbols are listed as ATLQ, ATLQU, ATLQW and ATLQR, the same as the current symbol for the shares
Name change to Atlantic Acquisition Corp I requires board and shareholder approval; CIK number remains unchanged
Rain Enhancement Technologies Holdco received a Nasdaq notice on August 18, 2026 stating it had not regained compliance with the $35 million market value of listed securities requirement. Unless the company obtained a hearing, its shares would face suspension and delisting from the Nasdaq Capital Market on August 27, 2026. The company requested a hearing before the Nasdaq Hearings Panel on August 21, 2026, and expects this to stay any delisting action, but the filing says the panel may not grant continued listing.
Nasdaq notice received August 18, 2026 said the company had not regained compliance with the $35,000,000 MVLS threshold.
Compliance deadline was August 17, 2026, after a 180-calendar-day period that started with a February 18, 2026 notice.
Company requested a hearing before the Nasdaq Hearings Panel on August 21, 2026.
Scheduled suspension and delisting date is August 27, 2026, unless a stay applies; the company says there is no assurance the panel will grant continued listing.
loanDepot, Inc. (NYSE: LDI) received a written notice from the New York Stock Exchange on August 21, 2026, saying its Class A common stock failed the $1.00 minimum price standard because its average closing price was below $1.00 over 30 consecutive trading days. The company has six months to regain compliance, and if it cannot, the NYSE will begin procedures to suspend and delist the stock, which matters to shareholders because it sets a firm deadline for a share price recovery or a possible reverse stock split.
The NYSE notice was received August 21, 2026, and the company said the average closing price was below $1.00 as of August 20, 2026.
The company has a six-month cure period to bring its share price and average share price back to at least $1.00.
The company must notify the NYSE of its intent to cure within 10 business days of receiving the notice.
A reverse stock split is among the options the company will consider; it would need stockholder approval no later than the next annual meeting, anticipated for early June 2027.
Global Interactive Technologies (GITS) received a Nasdaq notice on August 20, 2026, because it did not timely file its Form 10-Q for the quarter ended June 30, 2026, which Nasdaq Listing Rule 5250(c)(1) requires for continued listing. The company says it expects to file the 10-Q promptly, and its common stock will remain listed and traded during the 60-day grace period.
Nasdaq notice received August 20, 2026, for not timely filing the Form 10-Q for the quarter ended June 30, 2026
Company has 60 calendar days from the notice date to submit a plan to regain compliance
If Nasdaq accepts the plan, an exception of up to 180 days from the 10-Q due date, or until February 16, 2027, is possible
Common stock continues to trade on Nasdaq during the grace period, subject to other listing requirements
Citius Pharmaceuticals received a Nasdaq extension until February 8, 2027 to show its stock closes at or above $1.00 per share, a continued listing requirement. The filing says the extension has no effect on the current listing, but if compliance is not regained by that date, Nasdaq will issue a delisting notice and the company may appeal.
Nasdaq granted an extension to February 8, 2027 for the $1.00 per share bid price requirement under Rule 5550(a)(2)
Compliance requires a closing bid of $1.00 or more for at least ten consecutive business days before February 8, 2027
Common stock will continue trading on the Nasdaq Capital Market under CTXR for now
The company says there can be no assurance it will regain compliance
Breeze Acquisition Corp. II received a Nasdaq notice on August 20, 2026, saying it no longer complies with listing rules because it has not filed its Form 10-Q reports for the quarters ended March 31 and June 30, 2026. The notice has no immediate effect on the listing or trading of the company's securities, but the company must submit a plan to regain compliance by September 21, 2026, and Nasdaq may grant an exception to December 28, 2026, with no assurance that this will happen.
Nasdaq notice received August 20, 2026, citing Listing Rule 5250(c)(1) for late periodic filings
Delinquent Form 10-Qs cover the periods ended March 31, 2026 and June 30, 2026
Compliance plan due September 21, 2026; Nasdaq may grant an exception until December 28, 2026 if the plan is accepted
Notice has no immediate effect on listing or trading; company says it does not assure compliance within the required period
VivoSim Labs (VIVS) received a Nasdaq notice on August 17, 2026 saying its stock no longer met the $1 minimum bid price over 30 consecutive business days. The company has 180 calendar days, until February 16, 2027, to regain compliance, and its shares continue to trade on the Nasdaq Capital Market for now. The company has proposed a reverse stock split, which requires stockholder approval, and a failure to regain compliance could lead to delisting proceedings.
Nasdaq notice received August 17, 2026 under Listing Rule 5550(a)(2) for the $1 minimum bid price
Compliance deadline is February 16, 2027; regaining it requires a closing bid of at least $1 for ten consecutive business days
Proposed reverse stock split ratio range of 1-for-5 to 1-for-20, subject to stockholder approval in the 2026 annual meeting proxy
Notice has no immediate effect on listing or trading; ticker remains VIVS
Abbott agreed to resolve the Gill lawsuit and necrotizing enterocolitis claims for about 2,000 other infants for an aggregate of approximately $670 million, instead of continuing its appeal or paying about $600 million on the Gill judgment plus interest. The company states the agreements are a compromise and not an admission of liability, but the payment is a sizable cost, and roughly 1,700 lawsuits involving about 12,700 infants remain pending.
Gill case: July 2024 Missouri jury verdict of $495 million, affirmed by the Missouri Court of Appeals in May 2026.
Settlement: aggregate amount of approximately $670 million covering the Gill case and claims for about 2,000 additional infants.
Alternative cited: paying approximately $600 million, the Gill judgment plus accrued interest to date.
Remaining litigation: roughly 1,700 lawsuits involving claims for about 12,700 individual infants.
RenovoRx said Nasdaq confirmed on August 20, 2026 that it has regained compliance with the Nasdaq minimum bid price requirement, and Nasdaq considers the matter closed. The closing bid price was at or above $1.00 per share for the ten consecutive business days from August 6 through August 19, 2026. The filing removes a listing deficiency that had been pending since December 31, 2025, but it reports no financial results or business changes.
Nasdaq notified RenovoRx on December 31, 2025 that its stock had closed below $1.00 for 30 consecutive business days.
Nasdaq confirmed on August 20, 2026 that the closing bid price was $1.00 or greater for ten consecutive business days, August 6 through August 19, 2026.
Nasdaq considers the minimum bid price matter closed; the filing reports no financial results or other business developments.
Nasdaq notified BullFrog AI Holdings that it is eligible for a second 180-day period, until February 8, 2027, to regain the $1.00 minimum closing bid price, which the company has not yet met. The company plans to effect a reverse stock split before the period ends if the price is not cured organically, and failure to regain compliance would make its listed securities subject to delisting.
Nasdaq notice dated August 18, 2026; the first compliance period ended August 10, 2026.
Second Compliance Period runs until February 8, 2027; compliance requires at least $1.00 closing bid for a minimum of 10 consecutive business days.
Stockholders approved in October 2025 a reverse stock split ratio between 1-to-2 and 1-to-15, to be set by the Board.
The company states there is no assurance it will regain compliance during the period.
Aurinia Pharmaceuticals said it has settled patent infringement litigation with Teva Pharmaceuticals over Teva's application to sell a generic 7.9 mg voclosporin capsule in the United States. Under the settlement, Teva has stipulated that Aurinia's two U.S. patents are enforceable, valid and would be infringed, and Teva may launch no earlier than December 7, 2036, subject to earlier contingencies and FDA approval. The filing gives no financial figures, and Aurinia's other patent actions continue.
Teva stipulated that U.S. Patent Nos. 10,286,036 and 11,622,991 are enforceable, valid and would be infringed, and that the patents expire in December 2037.
Teva may launch its generic voclosporin no earlier than December 7, 2036, unless defined contingencies occur earlier.
Teva's U.S. launch also depends on FDA approval of its generic product.
Aurinia's patent infringement actions against five other companies continue in the U.S. District Court for the District of New Jersey.
The Metals Company said the National Oceanic and Atmospheric Administration published its consolidated application for an exploration license and commercial recovery permit for the TMC USA-A area in the Federal Register. The publication starts a public comment period that NOAA views as a prerequisite to certification, and NOAA still has to certify the application, complete an environmental review, and make a final licensing decision.
NOAA published the TMC USA-A consolidated application in the Federal Register; NOAA had determined the application fully compliant on April 28, 2026.
The application covers a proposed exploration and commercial recovery area of about 65,000 square kilometers, up from about 25,000 square kilometers in the April 2025 applications, with an estimated 619 million tonnes of wet nodules and pot
Remaining steps include certification, an environmental review with a draft Environmental Impact Statement for public comment, and a final determination on the license and permit.
The filing does not state a financial result, guidance change or timeline for a final NOAA decision.
Mereo BioPharma Group plc was told by Nasdaq that it has not yet regained the $1.00 minimum bid price required for continued listing, but it qualifies for an additional 180-day period, running to February 16, 2027. The notice has no immediate effect on the listing of its American Depositary Shares, though a failure to regain compliance by then would lead to a delisting notice that the company could appeal.
Nasdaq's first notice, dated February 17, 2026, set an initial compliance deadline of August 17, 2026.
On August 18, 2026, Nasdaq issued a second notice granting an additional 180 calendar days, until February 16, 2027.
Regaining compliance requires a closing bid price of at least $1.00 per share for 10 consecutive business days.
The company says the listing is unaffected for now and that it may consider options to regain compliance.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.